Anti-TRA monoclonal antibody

Pre-made anti-TRA monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to TRA/TRA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-INN071-Ab-1/ GM-Tg-hg-INN071-Ab-2Anti-Human TRA monoclonal antibodyHuman
GM-Tg-rg-INN071-Ab-1/ GM-Tg-rg-INN071-Ab-2Anti-Rat TRA monoclonal antibodyRat
GM-Tg-mg-INN071-Ab-1/ GM-Tg-mg-INN071-Ab-2Anti-Mouse TRA monoclonal antibodyMouse
GM-Tg-cynog-INN071-Ab-1/ GM-Tg-cynog-INN071-Ab-2Anti-Cynomolgus/ Rhesus macaque TRA monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-INN071-Ab-1/ GM-Tg-felg-INN071-Ab-2Anti-Feline TRA monoclonal antibodyFeline
GM-Tg-cang-INN071-Ab-1/ GM-Tg-cang-INN071-Ab-2Anti-Canine TRA monoclonal antibodyCanine
GM-Tg-bovg-INN071-Ab-1/ GM-Tg-bovg-INN071-Ab-2Anti-Bovine TRA monoclonal antibodyBovine
GM-Tg-equg-INN071-Ab-1/ GM-Tg-equg-INN071-Ab-2Anti-Equine TRA monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-INN071-Ab-1/ GM-Tg-hg-INN071-Ab-2; GM-Tg-rg-INN071-Ab-1/ GM-Tg-rg-INN071-Ab-2;
GM-Tg-mg-INN071-Ab-1/ GM-Tg-mg-INN071-Ab-2; GM-Tg-cynog-INN071-Ab-1/ GM-Tg-cynog-INN071-Ab-2;
GM-Tg-felg-INN071-Ab-1/ GM-Tg-felg-INN071-Ab-2; GM-Tg-cang-INN071-Ab-1/ GM-Tg-cang-INN071-Ab-2;
GM-Tg-bovg-INN071-Ab-1/ GM-Tg-bovg-INN071-Ab-2; GM-Tg-equg-INN071-Ab-1/ GM-Tg-equg-INN071-Ab-2
Products NameAnti-TRA monoclonal antibody
Formatmab
Target NameTRA
Protein Sub-locationIntrocelluar Protein
Category of antibodyTherapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-TRA monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-906Pre-Made Maslimomab Biosimilar, Whole Mab: Anti-T Cell Receptor (Tr, Tr Alpha_Beta) [human] therapeutic antibody
    Target AntigenGM-Tg-g-INN071-Ag-1Recombinant multi-species TRAR1/ TRAR2/ TRA protein


    Target information

    Target IDGM-INN071
    Target NameTRA
    Gene ID6955
    Gene Symbol and SynonymsIMD7,TCRA,TRA,TRA@
    Uniprot AccessionP0DSE1, P0DTU3
    Uniprot Entry NameTRAR2_HUMAN
    Protein Sub-locationIntrocelluar Protein
    CategoryTherapeutics Target, INN Index
    DiseaseCancer
    Gene EnsemblN/A
    Target ClassificationTumor-associated antigen (TAA)

    The target: TRA, gene name: TRA, also named as IMD7, TCRA, TCRD@, TRAC, TRA. Enables signaling receptor activity. Involved in T cell mediated cytotoxicity directed against tumor cell target and detection of tumor cell. Part of alpha-beta T cell receptor complex. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.